Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells

Journal of Pharmaceutical Sciences

Volumn 105, Issue 12, 2016, Pages 3645-3657

  Tima, Singkome ^a   Okonogi, Siriporn ^a   Ampasavate, Chadarat ^a   Pickens, Chad ^b   Berkland, Cory ^b   Anuchapreeda, Songyot ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

micelle; nanoparticle; peptides; polymeric drug delivery systems; targeted drug delivery

Indexed keywords

CD135 ANTIGEN; CURCUMIN; POLOXAMER; FLT3 PROTEIN, HUMAN; POLYMER;

ARTICLE; CONJUGATION; CONTROLLED STUDY; CYCLOADDITION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; HYDRATION; HYDROGEN BOND; LEUKEMIA CELL; MICELLE; PROTEIN EXPRESSION; SOLUBILITY; ANIMAL; BIOSYNTHESIS; CAT; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; PROCEDURES; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; CATS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; MICELLES; POLYMERS; PROTEIN STRUCTURE, SECONDARY;

EID: 84991239134     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.09.010     Document Type: Article

References (60)

1. 1 Rosnet, O., Bühring, H.J., Marchetto, S., et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10:2 (1996), 238–248.
2. 2 Carow, C.E., Levenstein, M., Kaufmann, S.H., et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 87:3 (1996), 1089–1096.
3. 3 Drexler, H.G., Meyer, C., Quentmeier, H., Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma 33:1-2 (1999), 83–91.
4. 4 Zheng, R., Levis, M., Piloto, O., et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood 103:1 (2004), 267–274.
5. 5 Meshinchi, S., Appelbaum, F.R., Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15:13 (2009), 4263–4269.
6. 6 Blume-Jensen, P., Hunter, T., Oncogenic kinase signaling. Nature 411:6835 (2001), 355–365.
7. 7 Stirewalt, D.L., Radich, J.P., The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3:9 (2003), 650–665.
8. 8 Wergeland, L., Oveland, E., Gry, S., et al. FLT3 internal tandem duplication involving its ubiquitin dependent endocytosis motif suspend modulation by Hdm2 and are associated with inferior survival in AML. Haematologica, 93(s1), 2008, 10.
9. 9 Kottaridis, P.D., Gale, R.E., Linch, D.C., FLT3 mutations and leukemia. Br J Haematol 122:4 (2003), 523–538.
10. 10 Kelloff, G.J., Crowell, J.A., Steele, V.E., et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130:2S Suppl (2000), 467S–471S.
11. 11 Duvoix, A., Blasius, R., Delhalle, S., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223:2 (2005), 181–190.
12. 12 Duvoix, A., Morceau, F., Schnekenburger, M., et al. Curcumin-induced cell death in two leukemia cell lines: K562 and Jurkat. Ann N Y Acad Sci 1010 (2003), 389–392.
13. 13 Kuo, M.L., Huang, T.S., Lin, J.K., Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells. Biochem Biophys Acta 1317:2 (1996), 95–100.
14. 14 Anuchapreeda, S., Tima, S., Duangrat, C., Limtrakul, P., Effect of pure curcumin, demethoxycurcumin, and bis demethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother Pharmacol 62:4 (2008), 585–594.
15. 15 Semsri, S., Krig, S.R., Kotelawala, L., Sweeney, C.A., Anuchapreeda, S., Inhibitory mechanism of pure curcumin on Wilms’ tumor1 (WT1) gene expression through the PKCα signaling pathway in leukemic K562 cells. FEBS Lett 585:14 (2011), 2235–2242.
16. 16 Tima, S., Ichikawa, H., Ampasavate, C., Okonogi, S., Anuchapreeda, S., Inhibitory effect of turmeric curcuminoids on FLT3 expression and cell cycle arrest in the FLT3-overexpressing EoL-1 leukemic cell line. J Nat Prod 77:4 (2014), 948–954.
17. 17 Anand, P., Kunnumakkara, A.B., Newman, R.A., Aggarwal, B.B., Bioavailability of curcumin: problems and promises. Mol Pharm 4:6 (2007), 807–818.
18. 18 Naksuriya, O., Okonogi, S., Schiffelers, R.M., Hennink, W.E., Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 35:10 (2014), 3365–3383.
19. 19 Yallapu, M.M., Nagesh, P.K., Jaggi, M., Chauhan, S.C., Therapeutic applications of curcumin nanoformulations. AAPS J 17:6 (2015), 1341–1356.
20. 20 Wang, K., Zhang, T., Liu, L., et al. Novel micelle formulation of curcumin for enhancing antitumor activity and inhibiting colorectal cancer stem cells. Int J Nanomedicine 7 (2012), 4487–4497.
21. 21 El-Dahmy, R.M., Elsayed, I., Elshafeey, A.H., Gawad, N.A., El-Gazayerly, O.N., Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. Int J Pharm 477:1-2 (2014), 39–46.
22. 22 Naksuriya, O., Shi, Y., van Nostrum, C.F., Anuchapreeda, S., Hennink, W.E., Okonogi, S., HPMA-based polymeric micelles for curcumin solubilization and inhibition of cancer cell growth. Eur J Pharm Biopharm 94 (2015), 501–512.
23. 23 Xu, W., Ling, P., Zhang, T., Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv, 2013, 2013, 340315.
24. 24 Yokoyama, M., Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 7:2 (2010), 145–158.
25. 25 Kabanov, A.V., Batrakova, E.V., Alakhov, V.Y., Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82:2-3 (2002), 189–212.
26. 26 Devi, D.R., Sandhya, P., Hari, B.N.V., Poloxamer: a novel functional molecule for drug delivery and gene therapy. J Pharm Sci Res 5:8 (2013), 159–165.
27. 27 Batrakova, E.V., Kabanov, A.V., Pluronic block copolymer: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 130:2 (2008), 98–106.
28. 28 Afghahi, A., Sledge, G.W. Jr., Targeted therapy for cancer in the genomic era. Cancer J 21:4 (2015), 294–298.
29. 29 Horne, G.A., Kinstrie, R., Copland, M., Novel drug therapies in myeloid leukemia. Pharm Pat Anal 4:3 (2015), 187–205.
30. 30 Kim, S.Y., Theunissen, J.W., Balibalos, J., et al. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood Cancer J, 5, 2015, e316.
31. 31 Gu, F.X., Karnik, R., Wang, A.Z., et al. Targeted nanoparticles for cancer therapy. Nano Today 2:3 (2007), 14–21.
32. 32 Sanna, V., Pala, N., Sechi, M., Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 9 (2014), 467–483.
33. 33 Perez-Herrero, E., Fernandez-Medarde, A., Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93 (2015), 52–79.
34. 34 Phongpradist, R., Chittasupho, C., Okonogi, S., et al. LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des 16:21 (2010), 2321–2330.
35. 35 Sahu, A., Kasoju, N., Goswami, P., Bora, U., Encapsulation of curcumin in pluronic block copolymer micelles for drug delivery applications. J Biomater Appl 25:6 (2011), 619–639.
36. 36 Duan, Y., Wang, J., Yang, X., Du, H., Xi, Y., Zhai, G., Curcumin-loaded mixed micelles: preparation, optimization, physiochemical properties and cytotoxicity in vitro. Drug Deliv 22:1 (2015), 50–57.
37. 37 Chittasupho, C., Manikwar, P., Krise, J.P., Siahaan, T.J., Berkland, C., cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol Pharm 7:1 (2009), 146–155.
38. 38 Punfa, W., Yodkeeree, S., Pitchakarn, P., Ampasavate, C., Limtrakul, P., Enhancement of cellular uptake and cytotoxicity of curcumin-loaded PLGA nanoparticles by conjugation with anti-P-glycoprotein in drug resistance cancer cells. Acta Pharmacol Sin 33:6 (2012), 823–831.
39. 39 Yallapu, M.M., Khan, S., Maher, D.M., et al. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials 35:30 (2014), 8635–8648.
40. 40 Wiernik, P.H., FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol 8:6 (2010), 429–436.
41. 41 Wander, S.A., Levis, M.J., Fathi, A.T., The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol 5:3 (2014), 65–77.
42. 42 Pemmaraju, N., Kantarjian, H., Andreeff, M., Cortes, J., Revandi, F., Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs 23:7 (2014), 943–954.
43. 43 Piloto, O., Levis, M., Huso, D., et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res 65:4 (2005), 1514–1522.
44. 44 Simon, T., Tomuleasa, C., Bojan, A., Berindan-Neagoe, I., Boca, S., Astilean, S., Design of FLT3 inhibitor-gold nanoparticle conjugates as potential therapeutic agents for the treatment of acute myeloid leukemia. Nanoscale Res Lett, 10(1), 2015, 466.
45. 45 Yang, T.F., Chen, C.N., Chen, M.C., Lai, C.H., Liang, H.F., Sung, H.W., Shell-crosslinked Pluronic L121 micelles as a drug delivery vehicle. Biomaterials 28:4 (2007), 725–734.
46. 46 Presolski, S.I., Hong, V.P., Finn, M.G., Copper-catalyzed azide-alkyne click chemistry for bioconjugation. Curr Protoc Chem Biol 3:4 (2011), 153–162.
47. 47 Khonkarn, R., Mankhetkorn, S., Hennink, W.E., Okonogi, S., PEG-OCL micelles for quercetin solubilization and inhibition of cancer cell growth. Eur J Pharm Biopharm 79:2 (2011), 268–275.
48. 48 Saladin, A., Rey, J., Thévenet, P., Zacharias, M., Moroy, G., Tufféry, P., PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces. Nucleic Acids Res 42 (2014), W221–W226.
49. 49 Schneider, S., Saladin, A., Fiorucci, S., Prévost, C., Zacharias, M., ATTRACT and P Tools: open source programs for protein-protein docking. Methods Mol Biol 819 (2012), 221–232.
50. 50 Verstraete, K., Vandriessche, G., Januar, M., et al. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. Blood 118:1 (2011), 60–68.
51. 51 Kurien, B.T., Singh, A., Matsumoto, H., Scofield, R.H., Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 5:4 (2007), 567–576.
52. 52 Sivakumar, K., Xie, F., Cash, B.M., Long, S., Barnhill, H.N., Wang, Q., A fluorogenic 1,3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes. Org Lett 6:24 (2004), 4603–4606.
53. 53 Turner, A.M., Lin, N.L., Issarachai, S., Lyman, S.D., Broudy, V.C., FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 88:9 (1996), 3383–3390.
54. 54 DaSilva, N., Hu, Z.B., Ma, W., Rosnet, O., Birnbaum, D., Drexler, H.G., Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia 8:5 (1994), 885–888.
55. 55 Meierhoff, G., Dehrnel, U., Gruss, H.J., et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 9:8 (1995), 1368–1372.
56. 56 Grafone, T., Palmisano, M., Nicci, C., Storti, S., An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev, 6, 2012, e8.
57. KB pathway with curcumin enhanced radiation-induced apoptosis in human Burkitt's lymphoma. J Pharmacol Sci 121:4 (2013), 247–256.
58. 58 Rao, J., Xu, D.R., Zheng, F.M., et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med, 9, 2011, 71.
59. 59 Mistry, P., Kelland, L.R., Loh, S.Y., Abel, G., Murrer, B.A., Harrap, K.R., Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro (cyclohexylamine) platinum (IV) (JM221) in human ovarian carcinoma cell lines. Cancer Res 52:22 (1992), 6188–6193.
60. 60 Wang, Y., Eksborg, S., Lewensohn, R., Lindberg, A., Liliemark, E., In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anticancer Drugs 10:10 (1999), 921–928.